HMA - Heads of Medicines Agencies
  • RSS
  • Sitemap
  • Contact
  • About HMA
  • Human Medicines
  • Veterinary Medicines
  • You are here:
  • Home
  • >Human Medicines
  • >CMDh
  • >Procedural Guidance
  • >Art 61.3 Procedure
  • CMDh
    • About CMDh
    • Statistics
    • Agendas and Minutes
    • Press Releases
    • COVID-19
    • BREXIT
    • Nitrosamine impurities
    • Procedural Guidance
      • General Info
      • Application for MA
      • eSubmissions
      • Generics
      • Applicant´s Responses
      • Renewal
      • Consultation with target patient groups
      • Variation
      • USR
      • Art 61.3 Procedure
      • Post Referral Phase
    • CMDh-Referrals
    • Product Information
    • Advice from CMDh
    • Templates
    • CMD Working Parties / Working Groups
    • Paediatric Regulation
    • Pharmacovigilance
    • Falsified Medicines
    • Questions & Answers
    • Contact Points
    • Recently Published history
  • MRI Product Index
  • Pharmacovigilance
  • Availability of Medicines
  • Publications and reports
  • National Contacts

 

Art. 61.3 Procedure

In order to view some of the documents on this website you need Acrobat Reader
(click here to download)

  • CMDh Standard Operating Procedure for Article 61(3) changes to patient information and the notification for product information amendment under Article 61(3) (not accompanying a variation change) (October 2011) [Track version]
  • Flowchart for the Article 61(3) procedure (July 2007)
  • Notification Form (June 2024) [PDF] [Tracked​​​​​​​]

For the United Kingdom, as of 1 January 2021, European Union law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland / NI.

  • Useful Links
  • Privacy Policy
  • Credits & Disclaimer
  • Contact
© Heads of Medicines Agencies - https://www.hma.eu/human-medicines/cmdh/procedural-guidance/art-613-procedure.html